Asston Pharmaceuticals Limited today announced the commencement of commercial production at its Unit II manufacturing facility, located at Plot No. W 18-A, MIDC, Additional Ambernath, Anand Nagar Industrial Area, District Thane, Maharashtra. The unit has begun operations with effect from January 21, 2026, marking an important milestone in the company’s growth and capacity expansion plans.
Unit II has been established to manufacture a wide range of pharmaceutical and nutraceutical products, strengthening Asston Pharmaceuticals’ ability to cater to the growing demand for high-quality healthcare and wellness solutions in India and international markets. The facility has been developed with a focus on modern manufacturing practices, regulatory compliance, and operational efficiency, in line with the company’s long-term vision of sustainable growth.
The new unit is strategically located in the MIDC Additional Ambernath industrial belt, which offers strong infrastructure, connectivity, and access to skilled manpower. This location is expected to enhance logistics efficiency and support timely supply to customers across key markets. With the commencement of commercial production, Asston Pharmaceuticals aims to significantly augment its manufacturing capacity and improve turnaround times, while maintaining stringent quality standards.
Unit II is equipped with advanced machinery and systems designed to meet current Good Manufacturing Practices (cGMP) and applicable regulatory requirements. The facility has been developed to support scalability and flexibility, enabling the company to introduce new products and formulations in response to evolving market needs. The manufacturing lines are capable of handling diversified product portfolios across pharmaceuticals and nutraceuticals, supporting both domestic consumption and export-oriented requirements.
In addition to enhancing production capabilities, the Unit II facility is expected to generate employment opportunities in the region and contribute to local economic development. Asston Pharmaceuticals has emphasized responsible manufacturing practices and adherence to environmental and safety norms as part of its operational philosophy.
With the commissioning of Unit II, Asston Pharmaceuticals Limited is well positioned to accelerate its growth trajectory, broaden its product offerings, and meet increasing demand across therapeutic and wellness segments. The company continues to focus on innovation, quality, and customer-centricity as it strengthens its manufacturing base and advances its long-term strategic objectives.
This milestone underscores Asston Pharmaceuticals’ intent to build robust infrastructure that supports consistent supply, regulatory compliance, and sustainable value creation for stakeholders. Asston Pharmaceuticals Limited is an Indian pharmaceutical and nutraceutical company based in Navi Mumbai that specialises in the manufacture, marketing and export of a wide range of healthcare products, including tablets, capsules, syrups, ointments, creams and sachets. Established in 2019, the company supplies affordable, quality medicines across domestic and international markets, with a notable presence in several African countries such as West and South Africa.
Asston operates its own manufacturing facilities, collaborates with WHO-GMP certified partners and works with NABL-accredited laboratories to ensure stringent quality standards. Its product portfolio spans multiple therapeutic categories and also includes nutraceutical formulations. The company has expanded its business model to include direct sales, contract manufacturing and loan licensing services.
